Aeglea Bio Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Welcome, everyone, to the 39th annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. The next presenting company is Aeglea. And presenting on behalf of the company, we have CEO, Anthony Quinn. Before I turn it over to Tony, I just wanted to highlight for those on the webcast would like to submit a question, please use the Ask a Question feature and the portal, and I'd be happy to ask the question on your behalf. With that, I'll turn it over to Tony.
Great. Thanks, Anupam. Thanks for the invitation. So good morning, everybody. I'm very pleased to join you virtually at this year's JPMorgan conference. So at Aeglea, we are thinking differently about the science of human enzymes. We're reimagining the potential of these natural catalysts to benefit people with rare
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |